KIT mutations associated with poor prognosis in GISTs
Based on a meta-analysis (18 studies; n=1487) reported in the World Journal of Surgical Oncology, KIT mutations in patients with gastrointestinal stromal tumors (GISTs) are associated with larger tumors (> 5 cm), higher mitotic activity (> 5), more frequent recurrences (OR = 2.06), more frequent metastases (OR = 2.77), and worse 3-year overall survival (OR = 0.47) compared to patients with PDGFRA mutations or wild-type.
Risk factors for CHC-related death identified
As reported in the World Journal of Gastroenterology, the following risk factors for chronic hepatitis C (CHC)-related deaths have been identified (n=8250 CHC patients; n=144 CHC-related deaths): α-IFN therapy (AOR=0.53); liver cirrhosis (AOR=2.89); hepatocellular carcinoma versus CHC (AOR=8.82); hypertension (AOR=1.76); alcohol consumption (AOR=1.73); and HBsAg positivity (AOR=22.28).
Infliximab is effective in corticosteroid-refractory ulcerative colitis
As reported in the Journal of Crohn’s & Colitis, treatment of corticosteroid-refractory ulcerative colitis patients with 3 doses of infliximab (n=113) resulted in short- (3 months) and long-term (12 months) colectomy rates of 18.6% and 25.6%, respectively. The RR of colectomy in patients with an elevated CRP and severe endoscopic lesions was 2.15 and 5.13, respectively.